Considerations Prior to Meeting With a Participant
EMBARK Psychedelic Therapy for Depression April 23, 2024 DOI: 10.1093/9780197762622.003.0005 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Practical guide or manual Peer reviewed |
|---|---|
| Key points | Argues that preparation for psychedelic-assisted therapy should include therapist credentialing, competencies, experiential training, supervision, and support, alongside thorough medical and psychiatric screening and informed consent. Proposes the EMBARK acronyms CUSHION and FRAZZLE for cultivating therapeutic presence, and recommends "enhanced consent" and "double consent" processes, while addressing touch controversies, physical space, music, cultural factors, dyad work, and family involvement. |
Abstract
AbstractChapter 4 provides a comprehensive guide to the considerations and treatment factors that should be attended to prior to initiating psychedelic-assisted therapy (PAT). It discusses the importance of therapists’ credentials, competencies, skills, personal growth, experiential training, personal psychedelic experiences, and personal commitment to receiving supervision, peer supervision, and support as a provider. It discusses the importance of cultivating a therapeutic presence using two illustrative EMBARK acronyms: CUSHION and FRAZZLE. The chapter also discusses the need for thorough screening for medical and psychiatric conditions, contraindications with other medications, and overall suitability. It includes a section on the consideration and controversies regarding the use of touch in psychedelic therapy, exploring both historical and current perspectives. An “enhanced consent” and “double consent” process is recommended. The chapter also addresses the setup of the physical space, the creation of appropriate music playlists, attendance to cultural factors, working in dyads, and considerations when involving other providers and the participant’s family members.
Citations in the library
Cites 217
- Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial Journal of Psychopharmacology November 30, 2016
- Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial Journal of Psychopharmacology November 30, 2016
- Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual significance Psychopharmacology July 7, 2006
- Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study. The Lancet Psychiatry May 17, 2016
- Trial of Psilocybin versus Escitalopram for Depression New England Journal of Medicine April 14, 2021
and 212 more in the library